G. Curigliano

发表

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).

M. A. Gouda, F. Janku, A. Wahida, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel Antibody-Drug Conjugates.

G. Marvaso, B. Jereczek-Fossa, L. B. Bielo, 2024, Critical reviews in oncology/hematology.

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer

C. Perou, K. Hoadley, N. Rashid, 2023, JAMA network open.

Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.

K. El Bairi, G. Curigliano, Ouissam Al Jarroudi, 2023, Cancer treatment and research.

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

D. Berton, S. Ellard, H. Arkenau, 2023, JAMA network open.

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

E. Crimini, M. Repetto, L. Ascione, 2024, The oncologist.

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

M. Fassan, F. D. De Braud, G. Curigliano, 2020, The oncologist.

Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer

C. Criscitiello, G. Fanelli, U. Malapelle, 2023, Pathologica.

The multicenter experience in the multidisciplinary Italian breast units: a review and update

G. Curigliano, M. Leonardi, C. Tinterri, 2023, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network.

A. Ponti, L. Marotti, M. Tomatis, 2023, European journal of cancer.

Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.

Luca Boscolo Bielo, Marcin Koziej, G. Curigliano, 2023, Cancer treatment reviews.

Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review

J. Blay, G. Curigliano, D. Moreira, 2024, ESMO open.

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants.

G. Curigliano, I. Rubio, L. Biganzoli, 2019, Breast.

Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow

C. Criscitiello, S. Tolaney, E. Dee, 2023, European journal of cancer.

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.

H. Rugo, P. Poortmans, O. Kaidar-Person, 2024, The Lancet. Oncology.

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

A. Vingiani, M. Dieci, G. Fucà, 2023, Therapeutic advances in medical oncology.

Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer

C. Criscitiello, L. Ascione, Chrysanthi Koukoutzeli, 2024, Clinical Medicine Insights: Oncology.

PARP Inhibitors for Breast Cancer Treatment: A Review.

C. Criscitiello, G. Bianchini, F. Giugliano, 2024, JAMA oncology.

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

S. Loi, A. Vincent-Salomon, M. Goetz, 2024, JAMA.

The evolving value assessment of cancer therapies: Results from a modified Delphi study

H. Larose, Myrto Lee, J. Grueger, 2024, Health Policy OPEN.

Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European SocieTy for Radiotherapy and Oncology (ESTRO).

H. Rugo, I. Mjaaland, B. Offersen, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study

A. Palazzo, Z. Ballatore, F. Pantano, 2023, The oncologist.

APOBEC3 mutagenesis drives therapy resistance in breast cancer

M. Ladanyi, S. Chandarlapaty, B. Weigelt, 2024, bioRxiv.

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

E. Crimini, Luca Boscolo Bielo, Gloria Pellizzari, 2024, Cancers.

Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers

E. Guerini-Rocco, E. Crimini, M. Repetto, 2024, The oncologist.

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

E. Crimini, E. Guerini Rocco, M. Repetto, 2024, The oncologist.

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

S. Loi, J. Balko, G. Sonke, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

M. Somerfield, I. Bedrosian, J. Boughey, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.